DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP™ is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
STIs can be a red flag for HIV risk
In a real-world study (n=214), 51% of people newly diagnosed with HIV had an STI history that included chlamydia, gonorrhea, or syphilis1
Behaviors that can result in an STI can also increase the risk of HIV. These may include sex2,3:
A record high of 2.3 million new cases of syphilis, gonorrhea, and chlamydia combined were diagnosed and reported in 20174
- Be the catalyst—start an open conversation with your patients about STIs and HIV risk
High HIV prevalence can mean high risk5,6
Talk to your sexually active patients in high-prevalence communities about DESCOVY FOR PrEP™
Patients can be at risk simply by being sexually active in regions, neighborhoods, or even social
networks with higher HIV prevalence.5,7
- 1 in 13 to
1 in 97
- 1 in 98 to
1 in 159
- 1 in 167 to
1 in 264
- 1 in 302 to
1 in 670
Individuals in all neighborhoods and communities can be at high risk for HIV.5
STI=sexually transmitted infection.